- Home
- DALN vs GOVX Comparison
DALN vs GOVX Comparison
Compare DALN & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- GOVX
- Stock Information
- Founded
- DALN 1954
- GOVX 2001
- Country
- DALN United States
- GOVX United States
- Employees
- DALN N/A
- GOVX N/A
- Industry
- DALN Newspapers/Magazines
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- DALN Consumer Discretionary
- GOVX Health Care
- Exchange
- DALN Nasdaq
- GOVX Nasdaq
- Market Cap
- DALN 24.6M
- GOVX 23.8M
- IPO Year
- DALN 2008
- GOVX N/A
- Fundamental
- Price
- DALN $6.70
- GOVX $2.11
- Analyst Decision
- DALN
- GOVX Strong Buy
- Analyst Count
- DALN 0
- GOVX 5
- Target Price
- DALN N/A
- GOVX $14.20
- AVG Volume (30 Days)
- DALN 52.2K
- GOVX 691.5K
- Earning Date
- DALN 03-05-2025
- GOVX 02-27-2025
- Dividend Yield
- DALN 2.39%
- GOVX N/A
- EPS Growth
- DALN N/A
- GOVX N/A
- EPS
- DALN N/A
- GOVX N/A
- Revenue
- DALN $128,286,000.00
- GOVX $3,090,161.00
- Revenue This Year
- DALN N/A
- GOVX N/A
- Revenue Next Year
- DALN N/A
- GOVX $150.51
- P/E Ratio
- DALN N/A
- GOVX N/A
- Revenue Growth
- DALN N/A
- GOVX N/A
- 52 Week Low
- DALN $2.98
- GOVX $1.09
- 52 Week High
- DALN $7.86
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- DALN 49.01
- GOVX 40.27
- Support Level
- DALN $6.75
- GOVX $2.04
- Resistance Level
- DALN $7.19
- GOVX $2.32
- Average True Range (ATR)
- DALN 0.32
- GOVX 0.18
- MACD
- DALN -0.13
- GOVX -0.02
- Stochastic Oscillator
- DALN 0.00
- GOVX 9.86
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.